Cleo Diagnostics Ltd (ASX: COV)
Health Care · Biotechnology · AU
AU$0.35
+4.55% today · -5.5% 1Y
Cleo Diagnostics Ltd (ASX: COV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $33.53M.
Over the last twelve months the share price has lost 5.5%, trading between 0.31 and 0.90.
Tweenvest scores Cleo Diagnostics Ltd across four factors: quality 27/100, value 43/100. Its strongest factor is value.
COV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $33.53M
- Revenue (TTM)
- $1.71M
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- 0.36
- 52-week high
- AU$0.90
- 52-week low
- AU$0.31
- Avg volume (3M)
- —
- Shares outstanding
- 137.11M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.10 | -1.39% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.85 | -0.31% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $149.36 | +0.40% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.04 | -0.33% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $825.94 | -0.91% |
| argenx SEENXTBR: ARGX | $64.17B | €889.60 | +1.18% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $150.52 | -5.23% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.